Clinical trial
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus…
NCT00369343 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00369343 |
|---|---|
| Title | Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women |
| Official title | A Multicenter, Randomized, 8-week, Double-blind, Placebo-controlled Study Followed by a 6-month Open-label Extension to Evaluate the Efficacy and Safety of DVS SR in Peri- and Postmenopausal Women With Major Depressive Disorder |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Depression, Depressive Disorder, Major |
| Intervention type | Drug |
| Interventions | Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR), Placebo |
| Enrollment | 381 |
| Start date | Sep 1, 2006 |
| Primary completion | Nov 1, 2007 |
| Completion | Jul 1, 2008 |
| First posted | Aug 29, 2006 |
| Last update posted | May 7, 2012 |
| Countries | United States |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: